Skip to main content
. 2023 Sep 21;20(2):416–436. doi: 10.1080/15548627.2023.2259216

Figure 8.

Figure 8.

Metformin attenuates crizotinib-induced cardiac complications in vivo. C57BL/6J mice (n = 10) were treated with vehicle, crizotinib (100 mg/kg), metformin (200 mg/kg) or metformin plus crizotinib for 6 weeks by means of intragastric administration. (A-C) the heart function of mice was measured by echocardiography. (D) serum was analyzed for CKMB level. n = 5. (E) H&E staining. Scale bar: 40 μm. (F) the cardiac remodeling gene expression relative to Actb in the indicated groups was shown. n ≥ 4. (G, H) Representative Sirius red and Masson-stained cardiac sections. Scale bar: 40 μm. (I) TEM observation of the left ventricle from C57BL/6J mice showed in (A). Representative images of the mitochondrial structure were shown on the left and enlarged views were presented on the right. Data were presented as mean ± SD. n = 3. The P value was calculated by one-way ANOVA with Sidak’s test (B to D and F). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, no significance. CTRL: control; Crizo: crizotinib.